Previous study has reported that PRMT5 promoted liver cancer cell growth through inhibiting BTG2 expression and the up‐regulation of cyclin E1 and cyclin D1.9 Therefore, we asked if down‐regulation of PRTM5 could reduce cyclin E1 and cyclin D1 expression in lung cancer cells. Here, PRMT5 is linked to lung carcinoma.